These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16773037)

  • 1. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
    Cardenas DD; Ditunno J; Graziani V; Jackson AB; Lammertse D; Potter P; Sipski M; Cohen R; Blight AR
    Spinal Cord; 2007 Feb; 45(2):158-68. PubMed ID: 16773037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
    Cardenas DD; Ditunno JF; Graziani V; McLain AB; Lammertse DP; Potter PJ; Alexander MS; Cohen R; Blight AR
    Spinal Cord; 2014 Jan; 52(1):70-6. PubMed ID: 24216616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
    Potter PJ; Hayes KC; Segal JL; Hsieh JT; Brunnemann SR; Delaney GA; Tierney DS; Mason D
    J Neurotrauma; 1998 Oct; 15(10):837-49. PubMed ID: 9814639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
    Hayes KC; Potter PJ; Hsieh JT; Katz MA; Blight AR; Cohen R
    Arch Phys Med Rehabil; 2004 Jan; 85(1):29-34. PubMed ID: 14970964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
    Goodman AD; Brown TR; Cohen JA; Krupp LB; Schapiro R; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Neurology; 2008 Oct; 71(15):1134-41. PubMed ID: 18672472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
    Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T; Henney HR
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-colony stimulating factor administration for neurological improvement in patients with postrehabilitation chronic incomplete traumatic spinal cord injuries: a double-blind randomized controlled clinical trial.
    Derakhshanrad N; Saberi H; Yekaninejad MS; Joghataei MT; Sheikhrezaei A
    J Neurosurg Spine; 2018 Jul; 29(1):97-107. PubMed ID: 29701561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial.
    Yang ML; Li JJ; So KF; Chen JY; Cheng WS; Wu J; Wang ZM; Gao F; Young W
    Spinal Cord; 2012 Feb; 50(2):141-6. PubMed ID: 22105463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
    Grijalva I; Guízar-Sahagún G; Castañeda-Hernández G; Mino D; Maldonado-Julián H; Vidal-Cantú G; Ibarra A; Serra O; Salgado-Ceballos H; Arenas-Hernández R
    Pharmacotherapy; 2003 Jul; 23(7):823-34. PubMed ID: 12885095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
    Morrow SA; Rosehart H; Johnson AM
    Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
    Hayes KC; Potter PJ; Hansebout RR; Bugaresti JM; Hsieh JT; Nicosia S; Katz MA; Blight AR; Cohen R
    Clin Neuropharmacol; 2003; 26(4):185-92. PubMed ID: 12897638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
    Casha S; Zygun D; McGowan MD; Bains I; Yong VW; Hurlbert RJ
    Brain; 2012 Apr; 135(Pt 4):1224-36. PubMed ID: 22505632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
    Lim JH; Muguet-Chanoit AC; Smith DT; Laber E; Olby NJ
    PLoS One; 2014; 9(12):e116139. PubMed ID: 25551385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.